Clinical Trial Update: Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update reporting safety and pharmacology data for SNX-5422 in combination with carboplatin and paclitaxel in patients with cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)
• SNX-5422

Snippet

Sponsor: Esanex Inc. | Conditions: Cancer | Phase 1 | Status: COMPLETED